Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.
We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.
We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
maybe part of the serendipity of getting older is running into people you lived with five years ago but haven’t spoken to in the same time and immediately turning around and inviting them to the party you’re going to and losing your voice singing drinking problem together
u can’t call it that it’s called biological autoluminescence or UPE. come on that’s like glowing human 101 a faux pas a lost room a pseudoscience. cifra said no no more than a decade ago. unfortunately, despite this, [classified]
Today in @NatureBiotech we report a new suit of PE8 prime editor proteins. PE8 variants were developed from laboratory-evolved PE6 proteins using AI-guided protein redesign. This approach combines recent advances in computational protein design and directed evolution to increase prime editing efficiency, especially in transient therapeutically relevant delivery settings such as mRNA+pegRNA electroporation into primary cells, eVLP delivery of prime editing RNPs, and LNP-mediated mRNA+pegRNA delivery in mice.
https://t.co/bz6PalFvc4
1/11